Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma

Ashley W. Jensen, Ivy A Petersen, Robert W. Kline, Scott L. Stafford, Paula J. Schomberg, Dennis M. Robertson

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: To determine the outcome of 125I plaque brachytherapy at our institution and identify the risk factors associated with the development of radiation complications, tumor recurrence, and metastasis. Patients and Methods: From 1986 to 2000, 156 patients underwent 125I episcleral plaque (COMS design) application for the treatment of ocular melanoma. Chart analysis of follow-up ophthalmologic appointments assessed the incidence of ocular side effects after therapy. Statistical analysis assessed outcomes and significant influencing factors. Results: With a median follow-up of 6.2 years, the 5-year overall survival was 83%. The 5-year disease-specific survival was 91%. Initial local control at 5 years was 92%, with 100% ultimate local control after secondary therapy that included 9 enucleations. The risk of metastasis was 10% at 5 years and 27% at 10 years. Vision stayed the same or improved in 25% of patients, and 44% of patients maintained visual acuity better than 20/200. Thirteen percent of patients experienced chronic pain or discomfort in the treated eye. Dose rates to the tumor apex greater than 90 to 100 cGy/h were associated with increased systemic control but worse radiation toxicity. Conclusion: Patients in our series experienced excellent local tumor control. Higher dose rates to the tumor apex were associated with reduced rates of distant metastases but worse ocular function.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume63
Issue number1
DOIs
StatePublished - Sep 1 2005

Fingerprint

Brachytherapy
Melanoma
tumors
Radiation
metastasis
radiation
Neoplasms
Neoplasm Metastasis
therapy
apexes
visual acuity
dosage
Survival
pain
charts
Chronic Pain
toxicity
statistical analysis
Visual Acuity
Appointments and Schedules

Keywords

  • I
  • Ocular melanoma
  • Outcome
  • Plaque brachytherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. / Jensen, Ashley W.; Petersen, Ivy A; Kline, Robert W.; Stafford, Scott L.; Schomberg, Paula J.; Robertson, Dennis M.

In: International Journal of Radiation Oncology Biology Physics, Vol. 63, No. 1, 01.09.2005, p. 101-108.

Research output: Contribution to journalArticle

Jensen, Ashley W. ; Petersen, Ivy A ; Kline, Robert W. ; Stafford, Scott L. ; Schomberg, Paula J. ; Robertson, Dennis M. / Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. In: International Journal of Radiation Oncology Biology Physics. 2005 ; Vol. 63, No. 1. pp. 101-108.
@article{ac0250fcc7674d1692dbf1007e547f3c,
title = "Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma",
abstract = "Purpose: To determine the outcome of 125I plaque brachytherapy at our institution and identify the risk factors associated with the development of radiation complications, tumor recurrence, and metastasis. Patients and Methods: From 1986 to 2000, 156 patients underwent 125I episcleral plaque (COMS design) application for the treatment of ocular melanoma. Chart analysis of follow-up ophthalmologic appointments assessed the incidence of ocular side effects after therapy. Statistical analysis assessed outcomes and significant influencing factors. Results: With a median follow-up of 6.2 years, the 5-year overall survival was 83{\%}. The 5-year disease-specific survival was 91{\%}. Initial local control at 5 years was 92{\%}, with 100{\%} ultimate local control after secondary therapy that included 9 enucleations. The risk of metastasis was 10{\%} at 5 years and 27{\%} at 10 years. Vision stayed the same or improved in 25{\%} of patients, and 44{\%} of patients maintained visual acuity better than 20/200. Thirteen percent of patients experienced chronic pain or discomfort in the treated eye. Dose rates to the tumor apex greater than 90 to 100 cGy/h were associated with increased systemic control but worse radiation toxicity. Conclusion: Patients in our series experienced excellent local tumor control. Higher dose rates to the tumor apex were associated with reduced rates of distant metastases but worse ocular function.",
keywords = "I, Ocular melanoma, Outcome, Plaque brachytherapy",
author = "Jensen, {Ashley W.} and Petersen, {Ivy A} and Kline, {Robert W.} and Stafford, {Scott L.} and Schomberg, {Paula J.} and Robertson, {Dennis M.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1016/j.ijrobp.2005.01.022",
language = "English (US)",
volume = "63",
pages = "101--108",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma

AU - Jensen, Ashley W.

AU - Petersen, Ivy A

AU - Kline, Robert W.

AU - Stafford, Scott L.

AU - Schomberg, Paula J.

AU - Robertson, Dennis M.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Purpose: To determine the outcome of 125I plaque brachytherapy at our institution and identify the risk factors associated with the development of radiation complications, tumor recurrence, and metastasis. Patients and Methods: From 1986 to 2000, 156 patients underwent 125I episcleral plaque (COMS design) application for the treatment of ocular melanoma. Chart analysis of follow-up ophthalmologic appointments assessed the incidence of ocular side effects after therapy. Statistical analysis assessed outcomes and significant influencing factors. Results: With a median follow-up of 6.2 years, the 5-year overall survival was 83%. The 5-year disease-specific survival was 91%. Initial local control at 5 years was 92%, with 100% ultimate local control after secondary therapy that included 9 enucleations. The risk of metastasis was 10% at 5 years and 27% at 10 years. Vision stayed the same or improved in 25% of patients, and 44% of patients maintained visual acuity better than 20/200. Thirteen percent of patients experienced chronic pain or discomfort in the treated eye. Dose rates to the tumor apex greater than 90 to 100 cGy/h were associated with increased systemic control but worse radiation toxicity. Conclusion: Patients in our series experienced excellent local tumor control. Higher dose rates to the tumor apex were associated with reduced rates of distant metastases but worse ocular function.

AB - Purpose: To determine the outcome of 125I plaque brachytherapy at our institution and identify the risk factors associated with the development of radiation complications, tumor recurrence, and metastasis. Patients and Methods: From 1986 to 2000, 156 patients underwent 125I episcleral plaque (COMS design) application for the treatment of ocular melanoma. Chart analysis of follow-up ophthalmologic appointments assessed the incidence of ocular side effects after therapy. Statistical analysis assessed outcomes and significant influencing factors. Results: With a median follow-up of 6.2 years, the 5-year overall survival was 83%. The 5-year disease-specific survival was 91%. Initial local control at 5 years was 92%, with 100% ultimate local control after secondary therapy that included 9 enucleations. The risk of metastasis was 10% at 5 years and 27% at 10 years. Vision stayed the same or improved in 25% of patients, and 44% of patients maintained visual acuity better than 20/200. Thirteen percent of patients experienced chronic pain or discomfort in the treated eye. Dose rates to the tumor apex greater than 90 to 100 cGy/h were associated with increased systemic control but worse radiation toxicity. Conclusion: Patients in our series experienced excellent local tumor control. Higher dose rates to the tumor apex were associated with reduced rates of distant metastases but worse ocular function.

KW - I

KW - Ocular melanoma

KW - Outcome

KW - Plaque brachytherapy

UR - http://www.scopus.com/inward/record.url?scp=26944469354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944469354&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.01.022

DO - 10.1016/j.ijrobp.2005.01.022

M3 - Article

C2 - 16111577

AN - SCOPUS:26944469354

VL - 63

SP - 101

EP - 108

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -